Alignments of curated global HIV-1 protein sequences available from the Los Alamos National Laboratory HIV Sequence Database as of September, 2013, were used to compute two mutually complementary mosaic sequences of the complete Gag and Pol proteins and to identify highly conserved regions within them. These regions were arranged into six distint proteins collectively referred to as HIVconsvX and the individual genes were inserted into simian adenovirus or poxvirus vectors to generate vaccines C1, C62 (not tested in HIV-CORE 006 due to delayed manufacturing), M3, and M4. In the HIV-CORE 006 trial, people living without HIV-1 in sub-Saharan Africa received either the vaccine regimen (C1-M3M4; n=72) or placebo (n=16) and were followed up for 40 weeks following the last vaccination. C1=ChAdOx1.tHIVconsv1. C1/P=C1 or placebo. C62=ChAdOx1.HIVconsv62. M3=MVA.tHIVconsv3. M4=MVA.tHIVconsv4. M3M4/P=M3M4 or placebo.
